MEDLIVE

2192
6.1700.16% ( -0.010 )
Delay Closed: Nov 16, 16:08:11

Overview

MEDLIVE (2192)

Medlive Technology Co., Ltd. operates an online professional physician platform in Mainland China and internationally. The company’s precision marketing and cor...

Open
6.145
High
6.270
Low
6.110
Prev. Close
6.180
Volume
363.00K
Turnover
2.24M
Avg Price
6.164
Bid/Ask Ratio
-33.33%
Amplitude
2.59%
52wk High
14.696
Volume Ratio
0.20
Turnover Ratio
0.05%
52wk Low
6.000
HK Mkt Cap
4.56B
Market CapHKD
4.56B
P/ETTM
11.62
P/EDynamic
12.25
P/EStatic
--
EPSTTM
0.531
EPSDynamic
0.504
EPSStatic
--
BVPS
7.48
P/B
0.82
HK Shares
738.34M
Dividend YieldTTM
5.11%
DividendTTM
0.315
Shares
738.34M
Min lot size
500
Currency
HKD

MEDLIVE Analyst Rating

View more

Forecast & Rating

Sep 23, 2026
Price forecast
HK$10.4669.50%
Forecast & RatingStrong buy
5analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 6

    Medlive opened down as much as 8% at 09:30 to HK$6.080 against the prior close of HK$6.620, then ground higher through the session to HK$6.600 by 13:40 and closed at HK$6.585, down only 0.53% — a low-open, near-full-recovery pattern. The early gap echoed the roughly 9% intraday slide, while daily buybacks running since late October (98,500 shares for HK$613,000 on November 3) absorbed supply; Fidelity's 1.017 million-share add at about HK$6.81 and CITIC Securities' reiterated Buy rating frame the session's HK$6.484 average price. Fundamentals and price position remain in tension: Q2 2026 revenue of HK$182.0 million rose 6.48% year on year, operating income rose 38.5% and net margin held at 51.25%, yet the shares are still down 33.01% year to date, below the MA60 of 6.917 and 56.13% under the 52-week high of 15.01, only 9.75% above yesterday's low of 6.00. Though with just 1.45 million shares traded, the durability of the rebound still needs volume confirmation.

  2. Nov, 5

    Medlive rose 2.70% to HK$6.65, extending a rebound built on buybacks: from 26 October to 3 November the company repurchased about 1.5 million shares for roughly HK$9.49 million, including 98,500 shares on 3 November. The stock spiked to HK$6.795 at 09:44 in the morning session, slid to HK$6.485 at 13:53, then recovered into the close. Q2 2026 revenue was HK$182.0 million, up 6.48% year on year, with net profit of HK$93.29 million (+9.62%), operating income up 38.5% and EPS of HK$0.1262 (+9.78%); Citic Securities reiterated its Buy rating. Even so, the price sits below its 60-day MA of HK$6.94 and is down 32.35% year to date, 55.7% below the 52-week high of HK$15.01 and just 8.66% above the 22 October low of HK$6.12, at 12.53x PE. Though revenue growth remains in single digits and turnover was only 0.18%, buybacks continue to underpin the shares.

  3. Nov, 3

    Medlive slipped 1.67% to HK$6.185, spiking to HK$6.300 in the early session, sliding to HK$6.130 in the afternoon and recovering to HK$6.260 at the close on 1.12 million shares worth HK$6.93 million, thin volume that left buyback support unable to offset moving-average pressure. The company repurchased 1.4015 million shares for about HK$8.88 million over six straight sessions from 26 October to 2 November, including 311,500 shares for HK$1.9616 million on 2 November, while Fidelity added 1.017 million shares at roughly HK$6.81. Interim net profit rose 4% to RMB160 million with a 13.09-cent dividend, against an 11.66x PE and 0.83x PB. The stock is down 37.08% year to date, 58.79% below its 52-week high of HK$15.01 and just 1.06% above the 22 October low of HK$6.12, still under MA20 of 6.434 and MA60 of 6.99, though the buyback remains small against a HK$4.57 billion market cap.

  4. Oct, 23

    Medlive opened at HK$6.12, its intraday low, then climbed through the afternoon session to HK$6.435 at 14:04 BJ before closing at HK$6.420, up 3.55% from the prior close of HK$6.20. The rebound off yesterday's HK$6.12 52-week low was supported by Citic Securities reaffirming its Buy rating, Fidelity adding 1.017 million shares at about HK$6.81, and an interim net profit up 4% to RMB160 million alongside a 13.09-cent dividend. Still, fundamentals sit uneasily against the price: Q2 revenue of HK$182 million rose 6.48% yoy, net profit 9.62% and operating income 38.5%, with PE at 12.1x and PB 0.86x, while the stock is down 34.69% year-to-date, 57.23% below its January 12 52-week high of HK$15.01, and below its MA20 of HK$6.553.

  5. Oct, 22

    Medlive fell 3.58% to HK$6.200 from the prior close of HK$6.430, tracing a high-open-then-drift-lower pattern in which the day high of HK$6.430 was set at the open and the low of HK$6.160 arrived at 15:40 in the Hong Kong afternoon session. Citic Securities reaffirmed its Buy rating and Fidelity added 1.017 million shares at roughly HK$6.81, yet neither stopped the slide. Interim net profit rose 4% to RMB160 million alongside a 13.09-cent dividend, while 96.137 million shares were released from pledge and re-pledged for a RMB300 million loan. Q2 2026 net profit grew 9.62% yoy, operating income 38.5% and net margin held at 51.25%, but the price sits below MA20 of 6.58 and MA60 of 7.18, down 36.93% year-to-date, 58.69% below the 52-week high of 15.01 and just 0.8% above the 52-week low of 6.15, with PE at 11.71 and PB at 0.83. Though the auditor switch from EY to Deloitte remains an overhang on governance perception.

News